Pfizer: Hemophilia B trials

The registry lists 33 Hemophilia B studies with Pfizer as lead sponsor. 5 are open to participants now and 18 have results posted.

Phase 1 1Phase 2 2Phase 3 13Phase 4 4No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsRecruitingNCT07923981Phase 3
• A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNot yet recruitingNCT07859527
• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Phase 3
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingNCT05568719Phase 3
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Phase 3
• Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia BCompletedNCT04286412Phase 4Results posted
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BActive, not recruitingNCT03861273Phase 3Results posted
• A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)CompletedNCT03587116Phase 3Results posted
• Understanding Hemophilia A and B Drug Dosage Administration PatternsTerminatedNCT03248141Results posted
• Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort StudyCompletedNCT02740413Results posted
• A Gene Therapy Study for Hemophilia BCompletedNCT02484092Phase 2Results posted
• Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in ChinaCompletedNCT02336178Phase 4Results posted
• An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia BCompletedNCT02213250Phase 1Results posted
• Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia BCompletedNCT01335061Phase 3Results posted
• BeneFIX Drug Use Results Survey [All-Case Surveillance]CompletedNCT01154231Results posted
• Study Evaluating Liver Transplantation in Haemophilia Patients in SpainCompletedNCT00927992Results posted
• Study Evaluating On-Demand Treatment With BeneFIX In Chinese SubjectsCompletedNCT00866606Phase 3Results posted
• Post Marketing Observational Study of Reformulated BeneFIXCompletedNCT00835068Results posted
• Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IXCompletedNCT00749476Phase 4Results posted
• Registry For Patients Treated With BeneFix In Usual Care Setting In GermanyCompletedNCT00714415Results posted
• Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia BCompletedNCT00484185Results posted
• Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia BCompletedNCT00364182Phase 3Results posted
• Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & BWithdrawnNCT06634836
• Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BTerminatedNCT03307980Phase 2
• Study Evaluating Approach to Treatment of Haemophilia A and B in SpainCompletedNCT00581438
• Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia BCompletedNCT00581126Phase 4
• Study Evaluating Allergic Reactions To Benefix In Hemophilia B PatientsCompletedNCT00244114
• Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia BCompletedNCT00195221
• Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual UseCompletedNCT00167973
• Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia BCompletedNCT00093210Phase 3
• Study Evaluating rFIX; BeneFIX® in Hemophilia BCompletedNCT00093171Phase 3
• Study Evaluating rFIX; BeneFIX in Severe Hemophilia BCompletedNCT00037557Phase 3